Last reviewed · How we verify
PBI-4050 and midazolam — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PBI-4050 and midazolam (PBI-4050 and midazolam) — Liminal BioSciences Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PBI-4050 and midazolam TARGET | PBI-4050 and midazolam | Liminal BioSciences Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PBI-4050 and midazolam CI watch — RSS
- PBI-4050 and midazolam CI watch — Atom
- PBI-4050 and midazolam CI watch — JSON
- PBI-4050 and midazolam alone — RSS
Cite this brief
Drug Landscape (2026). PBI-4050 and midazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/pbi-4050-and-midazolam. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab